BioPharma Credit PLC (BPCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioPharma Credit PLC (BPCR) has a cash flow conversion efficiency ratio of 0.029x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($33.76 Million) by net assets ($1.15 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BPCR net asset quality index to measure how much of total assets are equity-financed.
BioPharma Credit PLC - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how BioPharma Credit PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BPCR operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
BioPharma Credit PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioPharma Credit PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SFL Corporation Ltd
NYSE:SFL
|
0.067x |
|
Saregama India Limited
NSE:SAREGAMA
|
0.051x |
|
Fras-le S.A
SA:FRAS3
|
0.130x |
|
ORION Holdings Corp
KO:001800
|
0.036x |
|
Genco Shipping & Trading Ltd
NYSE:GNK
|
0.000x |
|
Northeast Bancorp
NASDAQ:NBN
|
-0.018x |
|
Guilin Fuda Co Ltd
SHG:603166
|
0.032x |
|
Jingjin Environmental Protection Co Ltd
SHG:603279
|
0.050x |
Annual Cash Flow Conversion Efficiency for BioPharma Credit PLC (2017–2024)
The table below shows the annual cash flow conversion efficiency of BioPharma Credit PLC from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market value of BioPharma Credit PLC.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.18 Billion | $111.91 Million | 0.095x | +3.09% |
| 2023-12-31 | $1.34 Billion | $123.18 Million | 0.092x | -33.31% |
| 2022-12-31 | $1.34 Billion | $184.28 Million | 0.138x | +94.80% |
| 2021-12-31 | $1.36 Billion | $96.44 Million | 0.071x | +67.91% |
| 2020-12-31 | $1.38 Billion | $58.07 Million | 0.042x | -55.05% |
| 2019-12-31 | $1.40 Billion | $131.52 Million | 0.094x | +92.59% |
| 2018-12-31 | $1.38 Billion | $67.14 Million | 0.049x | +94.57% |
| 2017-12-31 | $922.57 Million | $23.07 Million | 0.025x | -- |
About BioPharma Credit PLC
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in Leeds, the United Kingdom.